RxDoctor Payments Data

Janet Boone, NP

Family · Eastman, GANPI 1003388273

Payments from drug & device makers

$639in general payments, 2019–2025

Across 26 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$125
  • Corcept Therapeutics$107
  • Novo Nordisk$105
  • AbbVie$61
  • Aspira Women's Health Inc$53
  • Biohaven Pharmaceutical Holding Company Ltd.$50
  • plus $138 from 5 others

What the payments were for

  • Food & beverage$639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$639 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$24,285
Medicare patients
59
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide114$126,264
OzempicSemaglutide90$86,841
FarxigaDapagliflozin Propanediol116$84,841
LinzessLinaclotide66$50,450
RybelsusSemaglutide30$39,815
TrulicityDulaglutide27$26,294
JardianceEmpagliflozin23$23,220
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$20,131
EntrestoSacubitril/Valsartan16$14,466
EliquisApixaban16$11,272
Repatha SureclickEvolocumab12$6,618
Gabapentin189$2,234
Humalog Kwikpen U-100Insulin Lispro12$1,912
Potassium Chloride86$1,814
Testosterone Cypionate59$1,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$22$152,558141 claims
Novo NordiskOzempic, Rybelsus$105$126,655120 claims
AstraZenecaFarxiga, Breztri Aerosphere$19$104,972142 claims
AbbVieLinzess$61$50,45066 claims
PfizerEliquis$32$11,27216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in Eastman

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →